linjc16/ctgov huggingface dataset:
Opportunistic Salpingectomy at the Time of Benign Laparoscopic Hysterectomy

Study Overview
=================
Brief Summary
-----------------
In this prospective study, patients who underwent benign laparoscopic hysterectomy with systematic salpingectomy were included. The aim of this study is to assess the prevalence of tubal histopathological abnormalities such as Serous Tubal Intraepithelial Carcinoma (STIC) and tumor protein 53 (p53) signatures) as well as the prevalence of perioperative and postoperative complications related to opportunistic laparoscopic salpingectomy in a low risk population. The hypothesis is that prophylactic salpingectomy during benign laparoscopic hysterectomy is both feasible and innocuous. Peri- and postoperative complications, duration of salpingectomy and post-salpingectomy blood loss, histopathological and immunohistochemical analysis with anti-p53 antibody were evaluated.

Official Title
-----------------
Opportunistic Salpingectomy at the Time of Benign Laparoscopic Hysterectomy : Assessment of Possible Complications and Histopathological Tumor Protein 53 (p53)-Signatures

Conditions
-----------------
Benign Laparoscopic Hysterectomy, Systematic Salpingectomy

Intervention / Treatment
-----------------
* Other: Histopathologic tube anomalies


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients who underwent benign laparoscopic hysterectomy with systematic salpingectomy Exclusion Criteria: Hysterectomy in a context of gynecologic cancer Hysterectomy not carried out using laparoscopy Fimbriated end missing or damaged or impossible for pathologist to analyze

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Benign laparoscopic hysterectomy<br>Patients who underwent benign laparoscopic hysterectomy with systematic salpingectomy | Other: Histopathologic tube anomalies<br>* Assessment of prevalence of histopathologic tube anomalies (Serous Tubal Intraepithelial Carcinoma (STIC) or tumor protein 53 (p53) lesion)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Histopathologic tube anomalies | Prevalence of histopathologic tube anomalies (Serous Tubal Intraepithelial Carcinoma STIC or tumor protein 53 (p53) lesion) | day 1 of surgery |
Bacteriological Link Between Upper and Lower Airways in Cystic Fibrosis and Primary Ciliary Dyskinesia

Study Overview
=================
Brief Summary
-----------------
Cytobacteriological examination of sputum and bacteriological sampling in the middle meatus.

Official Title
-----------------
Bacteriological Link Between Upper and Lower Airways in Cystic Fibrosis and Primary Ciliary Dyskinesia

Conditions
-----------------
Cystic Fibrosis, Primary Ciliary Dyskinesia

Intervention / Treatment
-----------------
* Diagnostic Test: Middle meatus aspirations and sputum


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients over 6 years old Patients with cystic fibrosis or primary ciliary dyskinesia. Patients capable of performing an expectorations Patients having been informed of the research, having received the information note and not having opposed the research Exclusion Criteria: - Refusal to participate in the study

Ages Eligible for Study
-----------------
Minimum Age: 6 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients with Cystic Fibrosis and Primary Ciliary Dyskinesia<br> | Diagnostic Test: Middle meatus aspirations and sputum<br>* Bacterial genotype sequencing analysis will be performed in patients with bacteriological concordance between upper and lower airways.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Presence of bacterial colonization of the upper and lower airway |  | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| bacteriological concordance | bacteriological concordance of upper airways (VAS) and lower (VAI) between patients with cystic fibrosis and those with primary ciliary dyskinesia. | 1 day | 
| bacteria genotype | Compare the genotype of bacteria present in both VAS and VAI. | 1 day | 
| bacteriological concordance in children | Subgroup analysis (group <18 years old) | 1 day | 
| bacteriological concordance in adult | Subgroup analysis (adult group) | 1 day |
Ultrasonographic Evaluation of Fetal Adrenal Gland in Cases of Threatened Preterm Labor

Study Overview
=================
Brief Summary
-----------------
Preterm birth continues to be a major public health problem with lasting family and societal repercussions. Despite tremendous research effort, prevention strategies have failed, and the prevalence of preterm birth in the United States reached 12.3% in 2003. Prematurity causes 70% of fetal/neonatal deaths. 11.4% of births are at < 37 weeks' gestation. The rate of prematurity increases dramatically with the number of fetuses - singletons 10%; twins 54.9%; and triplets 93.6%

Official Title
-----------------
Ultrasonographic Evaluation of Fetal Adrenal Gland in Cases of Threatened Preterm Labor

Conditions
-----------------
Preterm Labor

Intervention / Treatment
-----------------
* Diagnostic Test: three dimensional ultrasound
* Diagnostic Test: color Doppler


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: singleton fetus less than 37 weeks of gestation women diagnosed to having Threatened preterm labor. presence of uterine contraction (at least 4 in 20 min or 8 in 60 min ) cervical effacement <80 % cervical dilatation <1 cm Exclusion Criteria: suspected fetal growth restriction, maternal medical complications, presence of fetal heart rate abnormalities at enrollment. Preterm Premature rupture of membranes Placenta previa Lower urinary tract infection or genital infection Fetal congenital anomaly
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| threatened preterm labor<br>women presented to the reception unit from 28-37 weeks by regular contractions and opened cervix | Diagnostic Test: three dimensional ultrasound<br>* evaluation of the suprarenal glands<br>Diagnostic Test: color Doppler<br>* Doppler evaluation of the suprarenal artery<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the volume of adrenal gland | measurement by three dimensional ultrasound | 5 minutes |
A Methodology Study in Healthy Subjects to Evaluate the Effect of AZD8309 After Nasal Administration of Lipopolysaccharide (LPS)

Study Overview
=================
Brief Summary
-----------------
The purpose of this methodology study is to evaluate the effect of AZD8309 on cells and inflammatory biomarkers in nasal lavage and blood after nasal challenge with lipopolysaccharide (LPS)

Official Title
-----------------
A Randomised, Double-blind, Placebo-controlled, Two-way Crossover, Single-centre Methodologhy Study in Healthy Subjects to Evaluate the Effect of Oral Dosing With AZD8309 on Cells and Inflammatory Biomarkers in Nasal Lavage and Blood After Nasal Challenge With Lipopolysaccharide (LPS).

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: AZD8309
* Drug: AZD8309


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy men or healthy, permanently sterilized, women aged 18 to 50 years inclusive, non-smokers or ex-smokers, Body Mass Index 18 to 30 kg/m2 and minimum body weight of 50 kg Blood neutrophil count above 2.2x10^9/L Exclusion Criteria: Clinical relevant disease and/or abnormality

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>AZD8309 | Drug: AZD8309<br>* oral solution 30 mg/g, dose: 300mg bid for 3 days<br>|
| Placebo Comparator: 2<br>Placebo | Drug: AZD8309<br>* oral solution 30 mg/g, dose: 300mg bid for 3 days<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Neutrophil numbers in nasal lavage |  | 3 times each in the end of two treatment periods | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cells and inflammatory biomarkers in nasal lavage |  | 3 times in the end of the two treatment periods | 
| Cells and inflammatory biomarkers in blood |  | 2 times in the beginning and 5 times in the end of the two treatment periods | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Healthy subjects, LPS, Effect, Intranasally
A Study to Evaluate the Safety and Efficacy of Prograf/FK778 and Prograf/MMF in de Novo Kidney Transplant Recipients

Study Overview
=================
Brief Summary
-----------------
A study to evaluate the safety and efficacy of Prograf/FK778 in de novo kidney transplant patients

Official Title
-----------------
A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Prograf®/FK778 and Prograf®/MMF in De Novo Kidney Transplant Recipients

Conditions
-----------------
Kidney Transplantation

Intervention / Treatment
-----------------
* Drug: FK778


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient is a recipient of a primary or retransplanted cadaveric or non-HLA-identical living donor kidney. Patient must receive first oral dose of randomized study drug within 48 hours of transplant procedure. Exclusion Criteria: Patient has received or is receiving an organ transplant other than kidney Patient has received a kidney transplant from a cadaveric donor >= 60 years of age.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: FK778|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of biopsy confirmed acute rejection (Banff Grade ≥ I) at 6 months. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 6 month patient and graft survival rates |  |  | 
| time to first biopsy confirmed acute rejection |  |  | 
| clinically treated acute rejection episodes |  |  | 
| treatment failure (up to 6 months) |  |  | 
| renal function (SrCl and CrCl) |  |  | 
| quantitation of CMV and polyomavirus viral load |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Malononitrilamide, immunosuppression, treatment efficacy, treatment outcome
Magnifying NBI Endoscopy for Gastric Condition

Study Overview
=================
Brief Summary
-----------------
Recently, the improved resolution with standard endoscopy allows the close observation of highly inflamed gastric mucosa without a magnifying view. In a previous study, the investigators established the endoscopic classification of H. pylori-infected stomach by non-magnifying standard endoscopy. One normal RAC pattern and three types of abnormal patterns were observed. Overall diagnostic accuracy for predicting H. pylori-infection was 91.6%. However, there is no comparison study predicting H. pylori-infection and precancerous gastric lesions between standard and magnifying endoscopy.

Detailed Description
-----------------
The investigators aimed to evaluate the diagnostic efficacies of non-magnifying standard endoscopy for predicting H. pylori-infection status and precancerous gastric conditions, compared to magnifying NBI endoscopy

Official Title
-----------------
Magnifying Narrow-band Imaging for Diagnosis of H. Pylori and Precancerous Gastric Conditions: Comparison With Standard Endoscopy

Conditions
-----------------
Gastritis H Pylori

Intervention / Treatment
-----------------
* Other: Magnifying narrow-band imaging endoscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Gastroscopy can be performed H. pylori test and pathological analysis can be performed Exclusion Criteria: Age < 20 or > 70 years Anemia (serum hemoglobin level < 10 g/dL) Severe systemic disease Advanced chronic liver disease Use of certain medications, including proton pump inhibitors, H2- receptor antagonists, or antibiotics History of H. pylori eradication History of gastric surgery Recent history of upper gastrointestinal bleeding

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Magnifying narrow-band imaging endoscopy|During endoscopy, gastric mucosal patterns would be examined by magnifying narrow-band imaging.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| H. pylori infection status | H. pylori positivity would be assessed using rapid urease test. | 1 month | 
| Degree of chronic gastritis | Gastric atrophy and intestinal metaplasia would be evaluated on the basis of histopathological examination (updated Sydney system). | 1 month |
Prophylactic Antibiotic Use in Hernioplasty

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether prophylactic antibiotic use in inguinal hernioplasty are effective in prevention of infectious complication.

Official Title
-----------------
Prophylactic Antibiotic Use in Inguinal Hernioplasty: A Placebo-controlled, Double-blind Trial

Conditions
-----------------
Inguinal Hernia

Intervention / Treatment
-----------------
* Drug: Antibiotic: cefazolin Sodium


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Primary inguinal hernia Elective surgery Must be older than 20 years of age Must not have any serious complication Exclusion Criteria: Incarceration Recurrence Drug allergy Diabetes mellitus Malignant diseases Serious heart diseases Psychological diseases Pregnancy Have been medicated with corticosteroids

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: cont<br> | Drug: Antibiotic: cefazolin Sodium<br>* 1g continuous IV at 30 minutes before starting operation<br>|
| Active Comparator: intervention<br> | Drug: Antibiotic: cefazolin Sodium<br>* 1g continuous IV at 30 minutes before starting operation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| infectious complication |  | two year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Recurrence of inguinal hernia |  | two year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Prophylactic, Antibiotic, Infection, Primary case
Midurethral Sling With Autologus Rectus Sheath

Study Overview
=================
Brief Summary
-----------------
assessment of the safety and efficacy surgeon tailored rectus sheath midurethral sling

Detailed Description
-----------------
the rectus sheath is harvested in 5 cm length and 2 cm width , A 2cm width 8 cm length polypropolyine mesh is attached to the harvest rectus sheet sling on both side The procedure is carried with a similar technique to the outside in TOT.

Official Title
-----------------
The Safety And Efficacy Of Autologus Rectus Sheath Fascia As A Midurethral Transobturator Tension Free Vaginal Tape For Treatment Of Stress Urinary Incontinence.

Conditions
-----------------
Stress Urinary Incontinence

Intervention / Treatment
-----------------
* Procedure: rectus sheath midurethral sling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: stress incontinence Exclusion Criteria: overactive bladder

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: rectus sheath midurethral sling|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cure rate of stress incontinence | history and urodynamic study | one year after surgery |
Bioequivalency Study of Torsemide Tablets Under Fed Conditions

Study Overview
=================
Brief Summary
-----------------
The objective of this study was the bioequivalence of a Roxane Laboratories' Torsemide Tablets, 20 mg, to Demadex® Tablets, 20 mg (Roche) under fed conditions using a single-dose, 2-treatment, 2-period, crossover design.

Official Title
-----------------
A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalency Study of 20 mg Torsemide Tablets Under Fed Conditions

Conditions
-----------------
Edema

Intervention / Treatment
-----------------
* Drug: Torsemide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening. Exclusion Criteria: Positive test for HIV, Hepatitis B, or Hepatitis C. Treatment with known enzyme altering drugs. History of allergic or adverse response to Torsemide or any comparable or similar product.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Torsemide|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bioequivalence |  | Baseline, Two period, Seven day washout |
Assessing the Bioavailability of Leading Phytonutrient Products

Study Overview
=================
Brief Summary
-----------------
This study will primarily test various phytonutrient-based supplements to see which gets absorbed into the body the best. The study will secondarily look at inflammatory markers in the urine to determine any change.

Detailed Description
-----------------
This study will primarily test various phytonutrient-based supplements to see which gets absorbed into the body the best. 120 mg of curcumin from brands Meriva, CurcElite, Lonvida, UltraCur, NovaSol. The study will secondarily look at inflammatory markers in the urine to determine any change.

Official Title
-----------------
Assessing the Bioavailability of Leading Phytonutrient Products

Conditions
-----------------
Inflammation

Intervention / Treatment
-----------------
* Dietary Supplement: Curcumin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age and gender Exclusion Criteria: Cannot take any phytonutrient or curcumin supplement five days prior to commencement.

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 49 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Meriva<br>120 mg of curcumin in Meriva. | Dietary Supplement: Curcumin<br>* Oral supplement<br>|
| Other: Longvida<br>120 mg of curcumin Longvida. | Dietary Supplement: Curcumin<br>* Oral supplement<br>|
| Other: NovaSol<br>120 mg of curcumin NovaSol | Dietary Supplement: Curcumin<br>* Oral supplement<br>|
| Other: CurcElite<br>120 mg of curcumin CurcElite | Dietary Supplement: Curcumin<br>* Oral supplement<br>|
| Other: UltaCur<br>120 mg of curcumin Ultracur | Dietary Supplement: Curcumin<br>* Oral supplement<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bioavailability | Blood Plasma | 0, 1, 2, 4, and 12 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
infalmmation, bioavailability